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Background: Allergic rhinitis and its impact on asthma (ARIA) document underlines
the link between upper and lower airways. Patients suffering from allergic rhinitis
frequently (up to 80%) show bronchial hyperreactivity (BHR).
Objectives: This study aimed at evaluating a group of subjects suffering from
persistent allergic rhinitis, with BHR but with nasal symptoms only, to investigate the
type and intensity of nasal symptoms, nasal and bronchial airflow, and BHR grade
during the pollen season.
Methods: One hundred and twenty one polysensitized rhinitics were investigated.
Total symptom score (TSS) was assessed in all patients. Rhinomanometry, spirometry
and methacholine bronchial challenge were performed in all patients.
Results: 65 (53.7%) patients had impaired FEF 25–75 values. TSS correlated with
nasal airflow (Po0:001) and BHR grade (Po0:001). Nasal airflow correlated with FEF
25–75 values (Po0:05) and BHR (Po0:001). FEF 25–75 values correlated with FEV1
levels (Po0:003), BHR grade (Po0:001), and nasal obstruction symptom (Po0:05).
Severe BHR correlated with FEV1 (Po0:05) and FEF 25–75 (Po0:03) values, nasal
airflow (Po0:05) and nasal symptoms (Po0:001).
Conclusions: This study evidences that early bronchial impairment is frequently
detectable in patients with persistent allergic rhinitis and BHR. Moreover, nasal function
is strictly related with bronchial calibre and BHR grade. Therefore, careful evaluation of
lower airways should be investigated in all rhinitics as suggested by the ARIA document.
& 2005 Published by Elsevier Ltd.Published by Elsevier Ltd.
U.O. ORL, Dipartimento Regionale Testa-Collo, Padiglione Specialita` (piano terzo), Ospedale San
oa, Italy. Tel.: +39 10 5552124; fax: +39 10 5556682.
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Allergic rhinitis is characterized by a cascade of
inflammatory events that cause symptom appear-
ance.
Close association between allergic rhinitis and
asthma has been reported.1,2 Moreover, allergic
rhinitis has been demonstrated to be a strong risk
factor for the onset of asthma in adults.3 Allergic
rhinitis and its Impact on Asthma (ARIA) document
underlines this strong link between upper and lower
airways.4 Moreover, ARIA document classifies aller-
gic rhinitis as persistent or intermittent. We
recently confirmed that this classification is ad-
herent to real life.5
Asthma is characterized by a reversible airflow
obstruction and forced expiratory volume/1 s
(FEV1) is considered the main parameter to
evaluate bronchial obstruction.6 Moreover, small
airways are involved in the pathogenesis of
asthma.7 The forced expiratory flow at the 25%
and 75% of the pulmonary volume (FEF 25–75)
might be considered as a measure of the caliber
concerning distal airways, particularly in subjects
with normal FEV1.
8 Thus, FEF 25–75 may be
envisaged as a marker of initial bronchial impair-
ment, as recently described by ourselves in
patients with allergic rhinitis alone.5,9
On the other hand, bronchial hyperreactivity
(BHR) is a paramount feature of asthma. Moreover,
BHR may be observed in a high proportion of
rhinitics, more than 80% in patients sensitized to
perennial allergens.5,9 In addition, Th2-dependent
inflammation is related with nasal symptoms and
airflow.10
On the basis of these considerations, we eval-
uated a group of patients suffering from persistent
allergic rhinitis and with BHR but perceiving nasal
symptoms alone, sensitized both to pollens and
perennial allergens. Thus, we aimed at investigat-
ing the type and intensity of nasal symptoms, nasal
and bronchial airflow, and BHR grade in these
patients during the pollen season.Materials and methods
Study design
The study included patients with pure allergic
rhinitis such as with perceived symptoms only to
upper airways level and with BHR. They were
sensitized both to pollens and perennial allergens.
We excluded all the subjects who referred presence
of asthma symptoms, including cough, wheezing,dyspnoea, and shortness of breathing, acute upper
respiratory infections and use of intranasal or oral
corticosteroids, and antihistamines within the
previous 4 weeks.
The study was approved by the Navy Hospital
Review Board and an informed consent was
obtained from patients.Subjects
One hundred and twenty-one subjects, 114 males
and 7 females, aged 21.573.1 years, were con-
secutively visited. We chose this type of patients as
it is the most representative in the common clinical
practice. As recently reported, about 70% of
patients with allergic rhinitis are polysensitized
and more than 70% of them have BHR during the
pollen season.5 All of them were Navy soldiers who
referred to Navy Hospital for nasal complaints
during the pollen season of 2003. A detailed clinical
history and a complete physical examination,
including allergy evaluation, were performed. All
of them were evaluated performing rhinomanome-
try, spirometry and methacholine bronchial chal-
lenge.
The diagnosis of allergic rhinitis was made on the
basis of a history of nasal symptoms and positive
skin prick test according with validated criteria.4
The most important perennial allergens are in
our geographic area: house dust mites (i.e. Derma-
tophagoides farinae and pteronyssinus), cat, and
dog.9 The most relevant pollen allergens are in our
geographic area: Parietaria judaica, grasses, olive
tree, birch, and hazel.5Skin prick test
Allergy was assessed by the presence of sensitiza-
tion to the most common classes of aeroallergens
by performing skin prick test. It was performed as
stated by the Italian Society of Allergy and Clinical
Immunology.11 The allergen panel consisted of the
following: house dust mites (D. farinae and
pteronyssinus), cat, dog, grasses mix, Compositae
mix, Parietaria officinalis, birch, hazel tree, olive
tree, Alternaria tenuis, Cladosporium, and Asper-
gilli mix; the concentration of allergen extracts
was 100 IR/mL (Stallergenes, Milan, Italy). A hista-
mine solution in distilled water (10mg/mL) was
used as positive control and the glycerol-buffer
diluent of the allergen preparations as negative
control. Each patient was skin tested on the volar
surface of the forearm using 1mm prick lancets
(Stallergenes, Milan, Italy). The skin reaction was
recorded after 15min by evaluating the skin
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extract in comparison with the wheal given by the
positive and the negative control. A wheal diameter
equal or greater than 3mm was considered a
positive reaction. Antihistamines were stopped 1
week before skin prick test.
Nasal symptoms
The following symptoms were assessed by the
patient, answering the questions made by the
investigator: nasal obstruction, sneezing, rhinor-
rhea, and itchy nose. Each symptom was evaluated
on the following scale: 0 ¼ absent, 1 ¼ mild
(symptom was present but was not annoying or
troublesome), 2 ¼ moderate (symptom was fre-
quently troublesome but did not interfere with
either normal daily activity or sleep), and
3 ¼ severe (symptom was sufficiently troublesome
to have interfered with normal daily activity or
sleep). Total symptom score (TSS) being the sum of
each individual symptom was considered.
Patients were subdivided according with TSS
grade as mild (TSSp6), moderate (TSS ¼ 6–8),
and severe (TSSX9).
Rhinomanometry
Nasal airflow was measured by active anterior
rhinomanometry. Patients wore a tight-fitting fa-
cemask, and with the mouth closed, breathed
through one nostril. A sensor, placed in the
contralateral nostril, recorded data on pre- and
post-nasal pressures via airflow and pressure
transducers. The instrument (ZAN 100 Rhino Flow
Handy II, ZAN, Messgeraete Gmbh, Germany) was
connected to a personal computer. The signals of
transnasal airflow and pressure were amplified,
digitized, and saved for statistical analysis.
Nasal airflow was reported as the sum of
recorded airflow through right and left nostrils in
milliliter per second at a pressure difference of
150 Pa across the nasal passage.
Four or more airflow measurements were per-
formed for each patient and the mean was
recorded when reproducible values were achieved.
Patients were subdivided according with nasal
airflow values as mild (4720mL/s), moderate
(451–720mL/s), and severe impairment
(o450mL/s).
Decongestion test
After baseline rhinomanometry, two sprays of
naphazoline (100mg/puff) were then applied pernostril. This drug is a potent a-adrenostimulator
inducing quick vasoconstriction. Rhinomanometry
was performed 5 and 10min after. The best result
was considered. Total nasal airflow volume and
percentage of reversibility were evaluated.Spirometry
It was performed by using a computer-assisted
spirometer (Pulmolab 435-spiro 235, Morgan, Eng-
land), with optoelectronic whirl flow meter. Spiro-
metry is performed as stated by ERS,12 using the
European Community for Steel and Coal (ECSC)
reference equations. If an airway obstruction was
present as detected by FEV1 values less than 80% of
the predicted, a test of bronchodilatation was
performed using a salbutamol metered dose of
200mcg. Reversibility was considered if an increase
of at least 12% of FEV1 from baseline was achieved,
according to international guidelines.13 About FEF
25–75, reversibility was considered when there was
an increase of at least 15% from baseline values.14
Patients were subdivided according with FEF
25–75 values as having normal (480% of pre-
dicted), mild (70–80% of predicted), or moderate
involvement of bronchial airflow (o70% of pre-
dicted).Methacholine bronchial challenge
It was performed to evaluate BHR only if basal FEV1
was equal or more than 80% of predicted. Aerosol
was delivered using a dosimetric computerized
supply (MEFAR MB3, Marcos, Italy). Subjects inhaled
increasing doses of methacholine, starting from
30 mg/mL. The scheduled doses consisted of the
following: 30, 30, 30, 60, 90, 150, 150, 300, 300,
300, 150 mg/mL as previously reported.5,9
The test was interrupted and considered positive
when FEV1 value was reduced by more or equal
than 20% of control or a maximal cumulative dose
of 1590 mg/mL was achieved. The threshold dose
causing a 20% fall of FEV1 (PD20) was calculated.Degree of BHR
Four arbitrary classes of BHR were considered: very
mild ¼ PD20/FEV1 4800 mg/mL, mild ¼ PD20/FEV1
ranging from 401 to 800 mg/mL, moderate ¼ PD20/
FEV1 ranging from 400 to 101 mg/mL, and
severe ¼ PD20/FEV1 o100 mg/mL as previously
reported.9
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Statistical analysis was performed using w2 test,
calculating confidential limits of the relative risk at
95%. Differences were considered significant if P
values were o0.05. Data are presented as mean-
s7standard deviation.Results
All rhinitics were consecutive subjects and no
adverse event was reported during the study.
Total symptom score (Table 1): Twenty-two
patients had mild TSS, 79 moderate TSS, and 20
severe TSS.
Nasal airflow (Table 2): Seventeen patients had
mild nasal airflow impairment, 62 moderate, and
42 severe.
FEF 25–75 values (Table 3): Fifty six patients had
normal values, 30 mild impairment, and 35 moder-
ate one.
BHR grade (Table 4): Five patients had very mild
BHR, 15 mild, 62 moderate, and 39 severe.
We then compared each parameter with others.
Total symptom score (Table 1): There was
significant association between TSS level and nasal
airflow (Po0:001). The percentage of nasal decon-
gestion correlated with TSS grade (Po0:05). More-
over, there was significant correlation between TSS
grade and BHR severity (Po0:001).
Nasal airflow (Table 2): There was significant
correlation between nasal airflow and FEF 25–75
values (Po0:05). In addition, nasal airflow values
correlated with BHR grade (Po0:001) and TSS
(Po0:03).
FEF 25–75 values (Table 3): There was significant
correlation between the lowest values of FEF 25–75
and FEV1 values, even though the FEV1 value was
always normal in all subjects (Po0:003). FEF 25–75
values correlated with BHR grade (Po0:001) and
nasal obstruction symptom (P ¼ 0:043).
It is noteworthy to highlight that all subjects
perceived nasal symptoms only as confirmed by
normal FEV1 values.Table 1 Relationships between TSS and other paramete
TSS Pts % FVC FEV1 FEF
o6 22 16.5 96.878.1 95.6711 85724
6–8 79 65.3 96.9710.3 98710.4 84.8721.4
9–12 20 18.2 93.3711.2 93.1711.2 82.6729.3
Pre-NAF, basal nasal airflow; Post-NAF, nasal airflow after decong
Significant associations between TSS level and nasal airflow (Po
BHR severity (Po0:001).BHR grade (Table 4): Severe BHR correlated with
the lowest FEV1 values (Po0:05) and FEF 25–75
values (Po0:003). Severe BHR correlated with the
lowest nasal airflow levels (Po0:05). Moreover,
patients with the more severe BHR perceived more
intense TSS (Po0:001), mainly concerning obstruc-
tion (Po0:03). In addition, there was association
with the grade of nasal decongestion (Po0:05).Discussion
We performed a study on a cohort of patients
suffering from persistent allergic rhinitis with
’ ’
perceived’’ nasal symptoms only and showing
BHR. It is to note that about a half of the patients
referring allergic nasal symptoms are polysensi-
tized and have BHR as recently reported.5 Thus,
this clinical profile is very common in the daily
medical setting. We therefore aimed to evaluate
the impact of persistent allergic rhinitis due to
polysensitization on nasal airflow, bronchial airflow,
and BHR grade.
First of all, more than half of patients showed
reduced FEF 25–75 values suggesting an early
bronchial impairment.
Secondly, nasal symptoms well correlated with
objective assessment of nasal airflow, thus con-
firming that subjective perception well reflects
objective nasal function as previously reported.10
In addition, clear relationship between symptom
severity and BHR grade was demonstrated.
Thirdly, nasal airflow well correlated with FEF
25–75 values and BHR: it means that reduced nasal
patency predisposes to bronchial impairment. All
these findings underline the importance of nasal
conditioning in assuring physiological ventilation. In
fact, if nasal respiration is impaired dry and cold air
penetrates into the bronchi, thus BHR and bron-
chial airflow limitation may occur.
Fourthly, FEF 25–75 may be envisaged as an early
marker of bronchial involvement in patients with
allergic rhinitis as it correlates with FEV1 values. In
fact, even though these patients had normal FEV1
values, a linear trend to a sub-obstructive state ofrs.
BHR Pre-NAF Post-NAF (mL/s)
3407277 618mL/s7168.2 735mL/s7110.9(+19%)
2147200 554mL/s7127.6 631mL/s7128.9(+14%)
1967107 374mL/s7124 493mL/s7112 (+32%)
estion.
0:001), and percentage of nasal decongestion (Po0:05), and
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Bronchial airflow impairment in patient allergic rhinitis and BHR 1611prossimal airways may be appreciated. Moreover,
early bronchial impairment correlates with BHR
grade. It means that the persistence of nasal
inflammation may affect lower airways inducing
both initial reduction of smaller airway calibre and
BHR.
Thus, all these findings underline the close
association regarding the relationship between
the functions of the nose and bronchial calibre
and reactivity. In other words, as nasal patency is
more compromised as bronchial airflow becomes
more impaired.
These issues confirm the very important concept
provided by ARIA document: the link between
upper and lower airways.4 Allergic rhinitis and
asthma should be considered as a single syndrome
involving two parts of the respiratory tract.15
Moreover, it is evident that these two disorders
affect each other. The pathophysiology of allergic
rhinitis is similar to that of asthma and their
responses to pharmacological and specific immuno-
logical interventions are comparable.16
Thus, this study highlights the link between
upper and lower airways in patients with allergic
rhinitis and BHR. Therefore, our data strengthen
the suggestion provided by ARIA document that a
new diagnostic approach should be carried out in
the patients with pure allergic rhinitis.
All rhinitics, even in absence of history suggest-
ing for asthmatic symptoms, must be evaluated
performing spirometry. If early bronchial impair-
ment is demonstrated, bronchial methacholine
challenge may be considered as supplemental exam
to achieve a more exhaustive evaluation in rhini-
tics. Moreover, rhinitics should be carefully fol-
lowed up to evaluate the possible onset of asthma.
In conclusion, our study underlines the frequent
early bronchial impairment in patients with allergic
rhinitis alone and supports the strong link between
upper and lower airways.References
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